Loading...
Loading...
Of the 4 tracked institutions holding IAT, 2 have a 3-year clone track record — 2 of them beat the S&P. Average holder's clone alpha: +8.4pt. It's a gauge of who owns the name, not just how many.
Alpha = the manager's 3-year clone return minus the S&P 500. A skilled roster is a stronger tell than a crowded one — though even skilled managers' edge doesn't reliably survive the 13F disclosure lag. Why →
Among the 4 tracked institutional investors we monitor, IAT (ISHARES TR) is held with a combined value of $3.03M across 56,287 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $1.67M. 2 funds increased their holdings. 2 funds reduced their position.
Total Institutional Value
$3.03M
Total Shares Held
56,287
Institutional Holders
4
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $1.67M | 0.00% | -7.4% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | $1.20M | 0.00% | +142.4% |
| 3 | FMR LLC | $100.75K | 0.00% | -48.7% |
| 4 | BlackRock, Inc. | $60.95K | 0.00% | +88.7% |
| Member | Type | Date |
|---|---|---|
| Thomas R Carper | Sell | Apr 2, 2020 |
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of IAT with a position worth $1.67M, representing 0.00% of their portfolio. In total, 4 institutional investors hold IAT with a combined value of $3.03M.
Institutional investors hold $3.03M worth of IAT stock across 4 positions. The largest institutional holder is CITADEL ADVISORS LLC with $1.67M in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For IAT, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their IAT positions.
Last Close
$63.74
2026-07-24
YTD
+15.5%
92% of 52-week range